The Singapore Immunology Network (SIgN) was conceptualized in 2005 and established in 2006 by the Agency for Science, Technology and Research (A*STAR) with the aim of expanding and strengthening immunology research in Singapore. By January 2008, a new 6,000 mlaboratory and office space was officially inaugurated as the home of SIgN, in the Immunos building at Biopolis, under the executive leadership of Professor Philippe Kourilsky and scientific directorship of Professor Paola Castagnoli. SIgN is presently led by Professor Laurent Renia, Executive Director. 

Mission and Objective

SIgN’s mission is to advance human immunology research, contribute scientific knowledge and make innovative discoveries to improve lives and further socio-economic growth. SIgN is committed to translate research findings into clinical and commercial applications, in partnership with clinics and industry. 


SIgN is home to ~200 national and international researchers and support staff working under 17 renowned Principal Investigators under the directorship of Professor Laurent Renia. The current SIgN researcher groups may be broadly categorized into three main areas of focus: Infectious DiseasesCancer and Immune Dysfunctions. Our researchers also have key interests and expertise in Inflammation, Immunotherapy, Aging, Allergy and Skin Disease.Our research activities are supported by a strong in-house cluster of cutting-edge technology platforms

SIgN is committed to lead in immunology research and nurture research talents. At SIgN, all researchers can expect a stimulating environment that promotes analytical thinking, interdisciplinary collaboration and entrepreneurial spirit.